Mayne Pharma Group Limited
(ASX:MYX) has entered into a binding agreement to acquire privately owned US based company Metrics.
The US pharmaceutical contractor is a provider of development services to the pharma industry which also develops and manufactures niche generic pharmaceuticals.
The acquisition includes an upfront payment of $102.5 million plus further payments of up to $14.6 million dependant on fiscal 2013 performance.
Mayne Pharma Group reported a full year net profit of $6.2 million for the 2012 financial year.
